Total
0
Shares
G Medical Innovations (ASX:GMV) - CEO, Dr Yacov Geva
CEO, Dr Yacov Geva
Source: Small Caps
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Meditech innovator G Medical (GMV) has completed an oversubscribed $6 million placement to professional, sophisticated, and institutional investors
  • The capital raised will be used for the repayment of loans and the termination of convertibles notes, with the balance to be used for working capital
  • The company has made great strides recently in gaining approvals and opening up new markets for its proprietary medical monitoring platforms
  • G Medical has faith the capital raised will enable sufficient balance sheet flexibility to fund near-term growth opportunities for its novel technologies
  • While the placement has resulted in some share dilution — and an according share price drop — the opportunities still on GMV’s horizon will likely see a bounce back
  • G Medical fell 8.8 per cent to 8.3 cents per share by market close on Friday

Meditech innovator G Medical (GMV) has completed an oversubscribed $6 million placement to professional, sophisticated, and institutional investors.

The capital raised will be used for the repayment of loans and the termination of convertibles notes, with the balance to be used for working capital.

Critical milestones

The company has made great strides recently in gaining approvals and opening up new markets for its proprietary medical monitoring platforms, including the Prizma device, the Vital Signs Monitoring System and the G Medical Patch.

G Medical has faith the capital raised will enable sufficient balance sheet flexibility to fund near-term growth opportunities for its novel technologies.

While some shareholders may be slightly off-put by yet another dilution, the share price has stayed quite solid through successive capital raises in recent months, and the market opportunities opening up for the company will re-instil some faith in GMV’s strategy.

G Medical CEO Dr Yacov Geva says the funds raised will serve as a great catalyst for growth in a time of great need for telehealth and remote monitoring services.

“Our solutions are becoming recognised as a cost-effective and scalable way to ease the burden on healthcare systems and may play a potentially pivotal role in the current environment.

“Board and management are constantly progressing a number of opportunities that will unlock considerable shareholder value and we look forward to providing ongoing updates when possible,” he added.

Next steps

The capital raise will allow G Medical to move forward with no debt burden from convertible notes, and with the funding flexibility to capitalise on emerging opportunities in key markets including the U.S., China and Europe.

While the placement has resulted in some share dilution — and an according share price drop — the opportunities still on GMV’s horizon will likely see a bounce back.

Given the share price fall has also been less than the dilutionary ratio, it seems the market mostly agrees with the sunny outlook of GMV’s management.

G Medical fell 8.8 per cent to 8.3 cents per share by market close on Friday.

GMV by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - CEO, Phillip Lynch

" Race Oncology (ASX:RAC) posts nominal decline in cash

Race Oncology (RAC) has posted a nominal decline in cash and equivalents as of 30 September 2021 to $8.94 million, down from $9.32...
Prescient Therapeutics (ASX:PTX) - Managing Director and CEO, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8...
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) highlights trial progress in September quarterly

Neuren Pharmaceuticals (NEU) has released its September quarterly report, highlighting the progress with its upcoming clinical trials.

" Invion (ASX:IVX) sees complete regression of tumours in breast cancer trial

Invion (IVX) shares have soared following its latest trial results, demonstrating a complete regression in tumours following in vivo treatment.